Chikungunya Virus
-
Chikungunya antibody identified at VUMC moves forward
Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center. Read MoreMar 4, 2021
-
New method tested to block chikungunya infection
Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies. Read MoreJun 14, 2019
-
Alphavirus “Achilles heel”
Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses. Read MoreMay 17, 2018
-
VUMC joins national effort to block global pandemics of potentially lethal viruses
The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika. Read MoreJan 11, 2018
-
Keep your coat on, virus!
A compound acting on serotonin receptors delays a critical step during reovirus cell entry, reducing viral infectivity. Read MoreSep 22, 2015
-
Vanderbilt researchers develop potential treatment to fight mosquito-borne chikungunya virus
In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States. Read MoreJul 8, 2015